Aviragen Therapeutics (AVIR) Misses Q1 EPS by 1c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q1 EPS of ($0.57), $0.01 worse than the analyst estimate of ($0.56).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• X Financial (XYF) Tops Q2 EPS by 438c
• Baird Reiterates Outperform Rating on Mercury Systems (MRCY), 'Establishing a Bullish Fresh Pick'
• Oil market bearish for crude, bullish for products, says TotalEnergies CEO